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a  b  s  t  r  a  c  t
Prostate  cancer  remains  one  of the  leading  causes  of  cancer  death  in  men  around  the  world,  regardless
of  intense  research  and  development  of novel  therapies  in  the  last  10 years.  One  of the  new  avenues
that  has  been  tested  – inhibition  of angiogenesis  – has  been  disappointing  so far  in  clinical  studies  in
spite of strong  evidence  that  determinants  of  angiogenesis  (e.g.  vascular  endothelial  growth  factor)  are
strongly  associated  with  disease  progression.  One  of  the  reasons  for  these  outcomes  may  be  our  poor
understanding  of  the  biology  of  angiogenesis  in prostate  cancer  (and  probably  other  cancers  as  well)
resulting  in  inhibition  of both  detrimental  and  favourable  molecules.  We  discuss  here novel  targeted
and  more  speciﬁc  approaches  to inhibit  angiogenesis  in  prostate  cancer  as well  as  a completely  new
therapeutic  modality  to do  this  – modulation  of  alternative  splicing  –  that  may  be applicable  to  other
molecules/biological  processes  as well.
© 2016  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
In the last 15 years, there has been an increase in the use of
drugs that target angiogenesis in cancers. The most well-known
anti-angiogenic drug is Bevacizumab (Avastin), a humanized mon-
oclonal antibody against vascular endothelial growth factor—A
(VEGF-A) that is approved to be used in various cancers like
colon cancer, non-small cell lung cancer or kidney cancer [1,2].
However, following the initial excitement regarding the use of
anti-angiogenics, they have not proven to induce a robust antitu-
moural treatment, with many clinical studies showing a modest
progression-free survival and overall survival [3]. Additionally,
side effects of such treatments may  be quite important [1]. While
there may  be several explanations for this situation, it is more and
more clear that we do not understand enough the vascular biology
of tumours as well as many functional aspects of the molecules
involved, therefore missing the chance to design more targeted
treatments. This article discusses the current state of using anti-
angiogenics in prostate cancer and our own work in ﬁnding a novel
angle from which this problem may  be solved.
∗ Corresponding author at: School of Physiology, Pharmacology and Neuro-
sciences, Faculty of Biomedical Sciences, University of Bristol, Dorothy Hodgkin
Building, Bristol BS1 3NY, UK.
E-mail address: sebastian.oltean@bristol.ac.uk (S. Oltean).
2. Is there a rationale for developing anti-angiogenics in
prostate cancer?
2.1. Prostate cancer
Prostate cancer (PCa) is the most commonly diagnosed cancer
in men  in the Western world. Given its incidence, PCa is one of the
most considerable burdens on health systems around the world
and accounts for a considerable number of death by cancer in men.
The latest analysis of cancer statistics shows that in USA ∼27,000
patients died of PCa in 2015 [4]. The mainstay of PCa therapy, aside
from surgical intervention, is formed by a combination of anti-
androgens, chemotherapy and radiation therapy. However, despite
adequate treatment, a signiﬁcant proportion of men  progress to
the metastatic castration-resistant form. It is therefore established
that new avenues need to be found to be able to tackle this dis-
ease effectively. Indeed, in the last years several novel treatments
involving immunomodulators, vaccines, epigenetic modiﬁers or
bone-speciﬁc agents have been developed [5–7].
2.2. Evidence for the importance of angiogenesis in PCa
progression
Induction of angiogenesis, the development of new vessels from
existing ones, has long been recognized as an essential requirement
for tumours to grow above a certain size and is therefore established
http://dx.doi.org/10.1016/j.phrs.2016.03.013
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Fig. 1. Basic mechanisms of splicing regulation. Positions of 5′ and 3′ splice sites, branch point (A) and polypyrimidine tract are shown. ESE and ESS: exon splicing enhancers
and  silencers respectively. ISE and ISS: intron splicing enhancers and silencers, respectively. Example of splicing regulation: binding of a splice factor (SF) to an ESE induces
selection of a neighbouring splice site while binding to an ISI inhibits it.
as one of the hallmarks of cancer [8]. However, since angiogenesis
should be more important in highly-vascularized cancers and not
slow-growing like PCa it is essential to understand whether PCa
progression is dependant on angiogenesis. In favour of this, several
preclinical and clinical studies have shown a strong association of
angiogenic factors with PCa. For example, VEGF, a main determi-
nant of angiogenesis, was  found to be increased in plasma and urine
of patients with advanced PCa, whereas the microvessel density
was strongly associated with Gleason score and metastasis [9–11].
2.3. Clinical trials using anti-angiogenics in PCa
Despite the above-mentioned evidence for the importance of
angiogenesis in PCa, trials with different anti-angiogenic inhibitors
combined with the main treatment for advanced PCa (Docetaxel
and Prednisone) have failed to this date to show an improvement in
overall survival [12]. There are several possible explanations for the
failure of these trials, including hetereogeneity in patient stages and
selection, treatment-related toxicities or activation of resistance
mechanism through induction of pro-angiogenic factors [12,13]. A
recent phase II trial concludes that combination of anti-angiogenics
(bevacizumab and lenalidomide—though arguably lenalidomide is
not a “pure” anti-angiogenic) is able to circumvent the toxicity and
may  have clinical beneﬁt [14]. Despite the insufﬁcient data for the
effectiveness of anti-angiogenic treatment in PCa, the above men-
tioned studies suggest that further research is required to establish
the exact mechanism of regulation of angiogenesis in tumours.
Are we inhibiting the right molecules? There is certainly room for
improvement.
3. Alternative splicing and novel therapeutics
3.1. Alternative splicing as an important post-transcriptional
regulation level
Splicing is the removal of introns from the pre-mRNA and join-
ing of exons to form the mature RNA. The splicing reaction is
catalyzed by the spliceosome, a macromolecular ribonucleoprotein
complex that assembles at splice sites (exon-intron junctions) and
removes introns through two  transesteriﬁcation reactions. Beside
splice sites (that have loose consensus sequences) the reactive sites
in a basic splicing unit include a branch point involved in the trans-
Fig. 2. Common models of AS. (A) Cassette exon. (B) Mutually exclusive exon. (C) Alternative 5′ splice site. (D) Alternative 3′ splice site. (E) Intron retention. (F) Alternative
promoter. (G) Alternative poly(A) site.
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Fig. 3. Regulation of alternative splicing by signalling. (A) In unstimulated cells, SR proteins reside in the cytoplasm. (B) Activation of trasmembrane receptors (for example
EGF-receptor) stimulates kinases such as SRPK1, which in turn phosphorylate SR proteins; they move into the nucleus to change the splicing pattern of various transcripts.
P,  denotes phosphorylated state.
esteriﬁcation reaction and a polypirimidine tract that binds crucial
splice factors (Fig. 1).
Alternative splicing (AS), the re-arrangement of exons, introns
or parts of exons and introns in various combinations to result in
multiple mature transcripts from the same pre-mRNA, has been
described more than 40 years ago. There are several modes of AS
with the main categories being: A) cassette exon – when an exon is
either included or excluded in the mature transcript; B) mutually
exclusive exons – a mature transcript contains either one of two
exons but not both at the same time; C) and D) 5′ and 3′ alternative
splice sites – resulting in inclusion/exclusion of parts of exons; E)
intron retention – when an intron is not excised and appears in the
mature RNA (Fig. 2). Combinations with other gene regulations lev-
els may  result in even more transcript diversity, e.g. F) alternative
promoters or G) alternative poly(A) sites (Fig. 2)
What has only recently been established though, is how exten-
sive AS is. Indeed deep sequencing studies have conclusively show
that more than 95% of human genes are alternatively spliced [15,16]
providing a rationale for the existence of the estimated hundreds
of thousands of proteins from only ∼22,000 genes [17]. The extent
of AS places this process as a major player in gene regulation and
therefore determinant of cell function.
Fig. 4. Different mechanisms for potential spliced-based therapeutics. (A) Splice-switching oligonucleotides. (B) Small molecule splicing modulators (red shape) can (i)
inhibit  activation of splice factors or (ii–iv) can modulate selection of splice sites.
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Fig. 5. VEGF splice variants. Selection of a distal splice site (DSS) in the terminal exon results in formation of anti-angiogenic “b” isoforms.
3.2. Regulation of AS
The decision to include or exclude a particular exon is based on
the interaction between cis-  and trans-acting trans-acting elements.
Cis elements consist of regions were splice factors bind. Depending
on the position and outcome of exon regulation they are divided in
exonic and intronic splicing silencers (ESS and ISS) or exonic and
intronic splicing enhancers (ESE and ISE) (Fig. 1).
Trans-acting regulatory molecules are splice factors – two  of
the most important classes that are ubiquitously expressed are
serine-arginine (SR) proteins and heterogenous ribonucleoproteins
(hnRNPs). A fair number of RNA-binding proteins have also been
described to be splice factors and are not included in either of these
two classes. Many of these have tissue-speciﬁc distribution or reg-
ulate deﬁned processes like brain functions or muscle development
– e.g. Nova, Rbm24 [18,19] or the epithelial state of a cell – ESRP1
and 2 [20,21].
Splice factors, similar to transcription factors, are integrated in
signalling pathways, such as those regulated by transmembrane
receptor activation. Binding of a signalling molecule to its receptor,
phosphorylates and thus activates a SF, which then translocates
into the nucleus to regulate processing of its target RNAs (Fig. 3).
3.3. AS and cancer
Given the extent of AS, it is not surprising that there are
thousands of isoforms speciﬁcally associated with disease progres-
sion, including oncogenesis [22]. Splicing variants are described in
almost every class of molecules, including growth factors, tyro-
sine receptors, tumour suppressors and oncogenes. Many times
the splicing isoforms have opposing functions e.g pro- or anti-
angiogenic, pro- or anti-apoptotic [see recent reviews [22,23]]. Two
recent reports in Nature highlight the close connection between
Myc, one of the most important oncogenes, and the splicing
machinery [24,25]. It is therefore not surprising that AS manipu-
lation has recently emerged as a novel area in which therapeutic
intervention may  be designed, with the general idea being to try
and switch isoforms that are characteristic to cancer and assist in
its progression, to their normal counterparts [26].
3.4. Modulation of splicing for therapeutic beneﬁt
One of the greatest advances in the development of splicing
therapeutics so far is the concept of splicing-switching oligonu-
cleotides (SSOs) (Fig. 4A). These are complementary sequences
designed to bind exon-intron junctions or intronic/exonic regula-
tory elements and thus affect splicing outcomes.
Another concept, that of small molecules splicing modulators
(smSM) that can be used in therapeutics, has also gained the inter-
est of the splicing ﬁeld recently. Theoretically smSMs  may be
designed at several levels that can affect splicing outcomes (Fig. 4B),
such as inhibitors of kinases that are speciﬁc regulators of splice
factors (like the example related to SRPK1 from our own work
described below), modulators of protein–protein or protein-RNA
interactions at splice sites or modulators of RNA tertiary structure
at splice sites.
For a long time there has been reluctance on whether splic-
ing therapeutics can be speciﬁc enough, given the large number
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of splice sites and their loose consensus sequences. However, the
unique characteristics of a splice site are given by many factors
including the secondary and tertiary RNA structure, interactions of
splice factors bound to those sites either with each other or with
RNA. Recently, two studies have screened large chemical libraries
for modulators of SMN  splicing in a quest to develop novel ther-
apeutics for spinal muscular atrophy [27,28]. Remarkably, deep
sequencing showed that their lead compounds are highly speciﬁc
(affect less than 10 additional splice sites). Speciﬁcally, one of the
reports describes that the mechanism of action of one of the com-
pounds is through disruption of the interaction between a splice
factor and RNA [28].
4. SRPK1 as a novel therapeutic target in PCa
Serine-arginine protein kinase 1 (SRPK1) is a kinase that phos-
phorylates SR- proteins and modulates their activity. It has been
shown to be upregulated in numerous cancers—breast, colon
andpancreatic carcinomas [29], hepatocellular carcinoma [30],
esophageal squamous carcinomas [31], ovarian [32] and lung can-
cers [33] or glioma [34]. We  have recently shown that it is strongly
upregulated in PCa tissues and correlates with disease stage and
invasion [35].
We  have reported previously [36] that SRPK1 is a key regula-
tor of the balance between two splice isoforms − VEGF165a, the
canonical one that is proangiogenic and VEGF165b, resulting from
an alternative 3′ splice site in the terminal exon (see Fig. 5) that
has been shown in numerous studies to be anti-angiogenic [37,38].
This is accomplished through phosphorylation of the splice factor
SRSF1. Moreover, knockdown of SRPK1 in a colon carcinoma cell
line decreased tumour growth and microvessel density [36].
Based on this data we enquired whether this is also true in
PCa. Knockdown of SRPK1 switched VEGF splicing towards the
antiangiogenic isoform in PC3 cells line and decreased tumour
growth in xenografts as well as microvessel density in tumours
[39]. Although SRPK1 has been shown to regulate other tumorigenic
functions [40], we have not found any evidence that SRPK1 changes
proliferation, migration or invasion in PC3 cells. Moreover, in a res-
cue experiment, we have shown that if VEGF is expressed from
a construct that cannot be spliced, it rescues the tumour growth
phenotype seen in SRPK1 knockdown cells, therefore suggesting
that the effect we see in PC3 is mainly due to affecting angiogen-
esis through a switch in VEGF splicing. Finally, in a therapeutic
proof-of-principle experiment we have shown that intraperitoneal
administration of a speciﬁc SRPK1 inhibitor (SPHINX) is able to
reduce tumour growth in an orthotopic mouse model of PCa.
Our human data on a cohort of 110 patients with PCa showed
that SRPK1 expression is strongly associated with disease stage and
invasion but not with Gleason score. This supports our ﬁndings in
the pre-clinical studies that SRPK1 is a determinant of angiogenesis
in PCa, as such it would not affect cell morphology (and therefore
Gleason score) but contribute to its aggressiveness by stimulating
angiogenesis.
5. Concluding remarks and future directions
The failure of clinical trials using antiangiogenics in PCa so far,
despite strong evidence that angiogenesis is crucial for PCa progres-
sion, has pointed out that we need to understand better the biology
of vessels and angiogenesis in tumours, the various functions of
angiogenic regulators and design better targeted treatments. Once
such example might be the inhibition of SRPK1, which is highly
expressed in PCa and drives expression of the pro-angiogenic VEGF
splice isoforms, and not the beneﬁcial anti-angiogenic ones, which
are also inhibited by the current anti-VEGF therapies.
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